184 related articles for article (PubMed ID: 9482930)
1. A splicing variant of a death domain protein that is regulated by a mitogen-activated kinase is a substrate for c-Jun N-terminal kinase in the human central nervous system.
Zhang Y; Zhou L; Miller CA
Proc Natl Acad Sci U S A; 1998 Mar; 95(5):2586-91. PubMed ID: 9482930
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of DENN/MADD, a TNF receptor binding protein, correlates with neuronal cell death in Alzheimer's disease brain and hippocampal neurons.
Del Villar K; Miller CA
Proc Natl Acad Sci U S A; 2004 Mar; 101(12):4210-5. PubMed ID: 15007167
[TBL] [Abstract][Full Text] [Related]
3. MADD, a novel death domain protein that interacts with the type 1 tumor necrosis factor receptor and activates mitogen-activated protein kinase.
Schievella AR; Chen JH; Graham JR; Lin LL
J Biol Chem; 1997 May; 272(18):12069-75. PubMed ID: 9115275
[TBL] [Abstract][Full Text] [Related]
4. Contrasting effects of IG20 and its splice isoforms, MADD and DENN-SV, on tumor necrosis factor alpha-induced apoptosis and activation of caspase-8 and -3.
Al-Zoubi AM; Efimova EV; Kaithamana S; Martinez O; El-Idrissi Mel-A; Dogan RE; Prabhakar BS
J Biol Chem; 2001 Dec; 276(50):47202-11. PubMed ID: 11577081
[TBL] [Abstract][Full Text] [Related]
5. The mitogen-activated protein kinase phosphatase-3 N-terminal noncatalytic region is responsible for tight substrate binding and enzymatic specificity.
Muda M; Theodosiou A; Gillieron C; Smith A; Chabert C; Camps M; Boschert U; Rodrigues N; Davies K; Ashworth A; Arkinstall S
J Biol Chem; 1998 Apr; 273(15):9323-9. PubMed ID: 9535927
[TBL] [Abstract][Full Text] [Related]
6. The human DENN gene: genomic organization, alternative splicing, and localization to chromosome 11p11.21-p11.22.
Chow VT; Lim KM; Lim D
Genome; 1998 Aug; 41(4):543-52. PubMed ID: 9796103
[TBL] [Abstract][Full Text] [Related]
7. Implication of TNF receptor-I-mediated extracellular signal-regulated kinases 1 and 2 (ERK1/2) activation in growth of AIDS-associated Kaposi's sarcoma cells: a possible role of a novel death domain protein MADD in TNF-alpha-induced ERK1/2 activation in Kaposi's sarcoma cells.
Murakami-Mori K; Mori S; Bonavida B; Nakamura S
J Immunol; 1999 Mar; 162(6):3672-9. PubMed ID: 10092829
[TBL] [Abstract][Full Text] [Related]
8. Human c-Jun N-terminal kinase expression and activation in the nervous system.
Kumagae Y; Zhang Y; Kim OJ; Miller CA
Brain Res Mol Brain Res; 1999 Apr; 67(1):10-7. PubMed ID: 10101227
[TBL] [Abstract][Full Text] [Related]
9. Activity and expression of JNK1, p38 and ERK kinases, c-Jun N-terminal phosphorylation, and c-jun promoter binding in the adult rat brain following kainate-induced seizures.
Mielke K; Brecht S; Dorst A; Herdegen T
Neuroscience; 1999; 91(2):471-83. PubMed ID: 10366004
[TBL] [Abstract][Full Text] [Related]
10. Role of the JNK pathway in NMDA-mediated excitotoxicity of cortical neurons.
Centeno C; Repici M; Chatton JY; Riederer BM; Bonny C; Nicod P; Price M; Clarke PG; Papa S; Franzoso G; Borsello T
Cell Death Differ; 2007 Feb; 14(2):240-53. PubMed ID: 16794604
[TBL] [Abstract][Full Text] [Related]
11. DENN/MADD/IG20 alternative splicing changes and cell death in Alzheimer's disease.
Mo Y; Williams C; Miller CA
J Mol Neurosci; 2012 Sep; 48(1):97-110. PubMed ID: 22678883
[TBL] [Abstract][Full Text] [Related]
12. Induction of marked apoptosis in mammalian cancer cell lines by antisense DNA treatment to abolish expression of DENN (differentially expressed in normal and neoplastic cells).
Lim KM; Chow VT
Mol Carcinog; 2002 Nov; 35(3):110-26. PubMed ID: 12410563
[TBL] [Abstract][Full Text] [Related]
13. A cytoplasmic inhibitor of the JNK signal transduction pathway.
Dickens M; Rogers JS; Cavanagh J; Raitano A; Xia Z; Halpern JR; Greenberg ME; Sawyers CL; Davis RJ
Science; 1997 Aug; 277(5326):693-6. PubMed ID: 9235893
[TBL] [Abstract][Full Text] [Related]
14. IG20, in contrast to DENN-SV, (MADD splice variants) suppresses tumor cell survival, and enhances their susceptibility to apoptosis and cancer drugs.
Efimova EV; Al-Zoubi AM; Martinez O; Kaithamana S; Lu S; Arima T; Prabhakar BS
Oncogene; 2004 Feb; 23(5):1076-87. PubMed ID: 14716293
[TBL] [Abstract][Full Text] [Related]
15. Early modifications in the expression of mitogen-activated protein kinase (MAPK/ERK), stress-activated kinases SAPK/JNK and p38, and their phosphorylated substrates following focal cerebral ischemia.
Ferrer I; Friguls B; Dalfó E; Planas AM
Acta Neuropathol; 2003 May; 105(5):425-37. PubMed ID: 12677442
[TBL] [Abstract][Full Text] [Related]
16. Lasting N-terminal phosphorylation of c-Jun and activation of c-Jun N-terminal kinases after neuronal injury.
Herdegen T; Claret FX; Kallunki T; Martin-Villalba A; Winter C; Hunter T; Karin M
J Neurosci; 1998 Jul; 18(14):5124-35. PubMed ID: 9651196
[TBL] [Abstract][Full Text] [Related]
17. Selective response of ternary complex factor Sap1a to different mitogen-activated protein kinase subgroups.
Strahl T; Gille H; Shaw PE
Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11563-8. PubMed ID: 8876175
[TBL] [Abstract][Full Text] [Related]
18. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain.
Hibi M; Lin A; Smeal T; Minden A; Karin M
Genes Dev; 1993 Nov; 7(11):2135-48. PubMed ID: 8224842
[TBL] [Abstract][Full Text] [Related]
19. Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKS): evidence for a divergence of the ERKs and JNKs pathways induced by Ret.
Chiariello M; Visconti R; Carlomagno F; Melillo RM; Bucci C; de Franciscis V; Fox GM; Jing S; Coso OA; Gutkind JS; Fusco A; Santoro M
Oncogene; 1998 May; 16(19):2435-45. PubMed ID: 9627110
[TBL] [Abstract][Full Text] [Related]
20. Identification of c-Jun NH2-terminal protein kinase (JNK)-activating kinase 2 as an activator of JNK but not p38.
Lu X; Nemoto S; Lin A
J Biol Chem; 1997 Oct; 272(40):24751-4. PubMed ID: 9312068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
